Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Atlanta Consulting Group Advisors LLC

Atlanta Consulting Group Advisors LLC boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 303.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,769 shares of the pharmaceutical company's stock after buying an additional 1,331 shares during the period. Atlanta Consulting Group Advisors LLC's holdings in Vertex Pharmaceuticals were worth $823,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of VRTX. Natixis Advisors LLC grew its stake in shares of Vertex Pharmaceuticals by 5.8% in the third quarter. Natixis Advisors LLC now owns 461,886 shares of the pharmaceutical company's stock valued at $214,813,000 after buying an additional 25,301 shares in the last quarter. Mizuho Securities USA LLC increased its stake in Vertex Pharmaceuticals by 289.0% during the third quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company's stock worth $35,994,000 after purchasing an additional 57,497 shares during the period. Ipswich Investment Management Co. Inc. boosted its stake in shares of Vertex Pharmaceuticals by 2.7% in the third quarter. Ipswich Investment Management Co. Inc. now owns 1,523 shares of the pharmaceutical company's stock valued at $708,000 after purchasing an additional 40 shares during the period. Coastline Trust Co grew its holdings in shares of Vertex Pharmaceuticals by 13.1% in the third quarter. Coastline Trust Co now owns 6,579 shares of the pharmaceutical company's stock valued at $3,060,000 after purchasing an additional 760 shares in the last quarter. Finally, Empirical Finance LLC lifted its holdings in Vertex Pharmaceuticals by 2.2% during the 3rd quarter. Empirical Finance LLC now owns 8,916 shares of the pharmaceutical company's stock worth $4,147,000 after buying an additional 190 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Trading Down 3.8 %

Shares of Vertex Pharmaceuticals stock traded down $18.26 during mid-day trading on Friday, hitting $465.70. 2,581,391 shares of the stock were exchanged, compared to its average volume of 1,180,121. The stock has a market capitalization of $119.93 billion, a price-to-earnings ratio of -234.02 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a twelve month low of $341.90 and a twelve month high of $519.88. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The company has a 50-day simple moving average of $476.39 and a 200 day simple moving average of $471.60.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same period in the previous year, the firm posted $3.67 EPS. Vertex Pharmaceuticals's revenue was up 11.6% on a year-over-year basis. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.82 EPS for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Director Sangeeta N. Bhatia sold 646 shares of the business's stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the sale, the director now owns 4,435 shares in the company, valued at approximately $2,217,500. The trade was a 12.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Jeffrey M. Leiden sold 3,784 shares of the firm's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the completion of the transaction, the chairman now owns 9,994 shares in the company, valued at $4,987,006. The trade was a 27.46 % decrease in their position. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

VRTX has been the topic of a number of recent research reports. Bank of America cut their price objective on Vertex Pharmaceuticals from $550.00 to $541.00 and set a "buy" rating on the stock in a research report on Monday, October 14th. Raymond James reissued a "market perform" rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. TD Cowen lifted their price target on Vertex Pharmaceuticals from $450.00 to $500.00 and gave the stock a "buy" rating in a research report on Tuesday, July 23rd. Piper Sandler increased their price objective on Vertex Pharmaceuticals from $500.00 to $535.00 and gave the company an "overweight" rating in a report on Friday, August 2nd. Finally, Truist Financial restated a "buy" rating and set a $550.00 target price (up from $508.00) on shares of Vertex Pharmaceuticals in a research report on Monday, August 5th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $499.12.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.